DC passes pharma rep licensing bill

Soon, pharma sales folk could be ticketed for repping without a license. The District of Columbia's governing council voted to require sales reps to obtain licenses, becoming the only jurisdiction in the country to do so.

The vote was close--seven to six. And the final measure lacked a provision that would have prohibited data-mining of doctors' prescribing habits. Nevertheless, the primary provision stands. Once licensed, reps could be suspended for fraudulent behavior.

- read the article in the Washington Post
- here's more from the Washington Business Journal

Related Articles:
DC to vote on rep-licensing bill. Report
Dr. Drug Rep tells all. Report
Top Lilly exec plays secret sales agent. Report

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.